Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Weleader Biomedical CoROCO:7713 42 PB Ratio is 2.83 as of Jul. 30, 2026, which is 3% below its 10-year median of 2.93. GuruFocus rates ROCO:7713 with a GF Score™ of 42/100. The stock has 5 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Weleader Biomedical Co ranks worse than 57.94% on this metric.
The historical rank and industry rank for Weleader Biomedical Co's PB Ratio or its related term are showing as below:
ROCO:7713'
s PB Ratio Range Over the Past 10 Years
Min: 2.46 Med: 2.93 Max: 3.92
Current: 2.83
During the past 6 years, Weleader Biomedical Co's highest PB Ratio was 3.92. The lowest was 2.46. And the median was 2.93.
ROCO:7713's PB Ratio is ranked worse than 57.94% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.04
vs ROCO:7713: 2.83
During the past 12 months, Weleader Biomedical Co's average Book Value Per Share Growth Rate was 8.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 21.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 34.30% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Weleader Biomedical Co was 46.30% per year. The lowest was 21.20% per year. And the median was 36.50% per year.
Back to Basics: PB Ratio
Weleader Biomedical Co (ROCO:7713) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Weleader Biomedical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Weleader Biomedical Co PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Weleader Biomedical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Weleader Biomedical Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Weleader Biomedical Co (ROCO:7713) has a PB Ratio of 2.83 as of Jul. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Weleader Biomedical Co and its competitors. This is near median its historical median of 2.93. Over the past decade, Weleader Biomedical Co's PB Ratio has ranged from 2.46 to 3.92. According to the industry distribution chart, Weleader Biomedical Co ranks #456 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 57.9%.
Is Weleader Biomedical Co's PB Ratio too high?
Weleader Biomedical Co's current PB Ratio of 2.83 is near median its 10-year median of 2.93. Over the past 10 years, this metric has ranged from a low of 2.46 to a high of 3.92. The Medical Devices & Instruments industry median PB Ratio is 2.04. Weleader Biomedical Co's value of 2.83 is 38.7% above this industry median. Based on the distribution chart, Weleader Biomedical Co ranks #456 out of 787 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Weleader Biomedical Co has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Weleader Biomedical Co ranks #456 out of 787 companies for PB Ratio. This places Weleader Biomedical Co in the lower half of its industry. The industry median PB Ratio is 2.04. Weleader Biomedical Co's value of 2.83 is 38.7% above this benchmark. Historically, Weleader Biomedical Co's own PB Ratio has ranged from 2.46 to 3.92 over the past decade. While the company's 10-year median is 2.93 vs. the industry median of 2.04, Weleader Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.04, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Weleader Biomedical Co's current PB Ratio of 2.83 is 38.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Weleader Biomedical Co and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Weleader Biomedical Co's current PB Ratio is 2.83, which is near median its own 10-year median of 2.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current PB Ratio of 2.83. The current PB Ratio is 2.83, which is near median its 10-year median of 2.93 and 38.7% above the Medical Devices & Instruments industry median of 2.04. Weleader Biomedical Co's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current PB Ratio is 2.83 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
42GF Score
Get the complete analysis for ROCO:7713
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7713 has been successfully added to your 
